Cambridge, United Kingdom
Artios, founded in 2016, is a UK-based biopharma innovator prominently focused on the DNA Damage Response (DDR) pathway to combat cancer. With their proprietary DcoDeR platform, Artios leverages its expertise in DNA damage biology and drug discovery to develop targeted therapies addressing high unmet needs across solid tumor indications. The company's robust pipeline includes breakthroughs like the ATR inhibitor, ART0380, and the Polθ inhibitor, ART6043, which can be utilized as monotherapy or in combination treatments.
Strategic collaborations with top institutions such as Cancer Research UK and The Institute of Cancer Research enhance their research endeavors. The company’s latest financial achievement, a £110.00M Series C investment secured in July 2021, involved notable investors including Pfizer Venture Investments and RTW Investments. Artios presents a compelling opportunity for investors seeking impactful advancements in oncology therapeutics.
Nimbus Therapeutics